Brief: TransCode Therapeutics Says Cash & Cash Equivalents Sufficient To Fund Planned Operations Into Q1 2023
31/03/2022 22:22
March 31 (Reuters) - TransCode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS - CASH & CASH EQUIVALENTS
SUFFICIENT TO
FUND PLANNED OPERATIONS INTO Q1 2023
Source text for Eikon: ID:nGNX1Tgp5J
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors